Antipseudomonal treatment decisions during CF exacerbation management.

[1]  D. Sanders,et al.  A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. , 2021, American journal of respiratory and critical care medicine.

[2]  L. Hoffman,et al.  Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  P. Flume,et al.  Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[4]  J. Davies,et al.  Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[5]  P. Steyger,et al.  Aminoglycoside-Induced Cochleotoxicity: A Review , 2017, Front. Cell. Neurosci..

[6]  R. Pettit,et al.  Piperacillin‐tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients , 2017, Pediatric pulmonology.

[7]  H. Elphick,et al.  Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[8]  N. Morris,et al.  IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  V. Waters,et al.  Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2015, The Cochrane database of systematic reviews.

[10]  W. Morgan,et al.  Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11]  Karen A Robinson,et al.  Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .

[12]  S. Aaron.  Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. , 2007, Paediatric respiratory reviews.

[13]  Charles A. Johnson,et al.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. , 2007, The Journal of pediatrics.

[14]  M. Hogardt,et al.  Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[16]  F. Ratjen,et al.  Cystic fibrosis , 2003, The Lancet.

[17]  Margaret Rosenfeld,et al.  Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. , 2002, American journal of respiratory and critical care medicine.

[18]  P. Baghurst,et al.  Efficacy of once‐daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study * , 2001, Pediatric pulmonology.

[19]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[20]  G. Redding,et al.  Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .

[21]  A. Giunta,et al.  Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. , 1987, The Pediatric infectious disease journal.

[22]  D. Goldmann,et al.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. , 1983, The Journal of infectious diseases.